Skip to main content
Equibles
CRMD logo

CRMD · CorMedix Inc.

Track CRMD — free

Use CRMD with AI

Ask our own analyst here, or connect this data to the AI you already use.

Ask ALVIS about CRMD

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

or use your own AI

The free Equibles MCP server lets any client query SEC filings, earnings calls, KPIs, holdings and prices directly — read-only, OAuth-secured, cited to the filing.

ChatGPT Claude Gemini
Server URL
https://mcp.equibles.com/mcp
All connection guides →
$7.54 -0.60 (-7.37%) At close · Aug 14
Market Cap
$587.70M
Shares
77.94M

CorMedix Inc. Earnings Call Transcripts

Every quarterly earnings call for CorMedix Inc. (CRMD) — the full transcript with speaker labels, the audio replay, AI call highlights and a management-tone score, plus the matching 8-K earnings release and the quarter's 10-Q or 10-K. Investor days and conferences appear here too.

Revenue & result across quarters

Revenue Net income YoY up YoY down artefacts
▼82.1% $6,817 −$6.85M '22 Q3 22-11-10 ▼47.3% $29,702 −$8.21M '22 Q4 23-03-30 · $806,119 −$14.15M '24 Q2 24-08-14 · $11.46M −$2.78M '24 Q3 24-10-30 · $39.08M $20.64M '25 Q1 25-04-08 ▲4829.4% $39.74M $19.83M '25 Q2 25-08-07 ▲810.2% $104.28M $108.56M '25 Q3 25-10-20 · $128.62M $14.02M '25 Q4 26-03-05 ▲226.1% $127.43M $38.60M '26 Q1 26-05-14 LATEST ▲156.5% $101.93M $25.99M '26 Q2 26-08-13
Earnings call
FY26 · Q2
2026-08-13
CorMedix Inc. Q2 FY2026 Earnings Call
Revenue
$101.93M
▲ 156.5% YoY
Diluted EPS
$0.29
▲ 3.6% YoY
Gross margin
75.7%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY26 · Q1
2026-05-14
CorMedix Inc. Q1 FY2026 Earnings Call
Confident tone DefenCath commercial performance and TDAPA transition ReZZAYO ReSPECT Phase III results and sNDA preparation NUTRI-GUARD TPN Phase III enrollment challenges
Revenue
$127.43M
▲ 226.1% YoY
Diluted EPS
$0.43
▲ 43.3% YoY
Gross margin
82.5%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q4
2026-03-05
CorMedix Inc. Q4 FY2025 Earnings Call
Positive tone DEFENCATH TDAPA transition 2026/2027 financial guidance and adjusted EBITDA RIZEAO Phase III RESPECT trial
Revenue
$128.62M*
Gross margin
83.4%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY25 · Q3
2025-10-20
CorMedix Inc. Q3 FY2025 Earnings Call
Confident tone DefenCath commercial performance and TDAPA Melinta acquisition and integration Pricing and ESRD rule/legislation
Revenue
$104.28M
▲ 810.2% YoY
Diluted EPS
$1.26
Gross margin
89.3%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q2
2025-08-07
CorMedix Inc. Q2 FY2025 Earnings Call
Confident tone DefenCath Commercial Launch / LDO Rollout Melinta Therapeutics Acquisition Capital Structure and Financing
Revenue
$39.74M
▲ 4829.4% YoY
Diluted EPS
$0.28
Gross margin
95.3%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q1
2025-04-08
CorMedix Inc. Q1 FY2025 Earnings Call
Confident tone DefenCath commercial launch and net sales TDAPA reimbursement and Medicare Advantage Inpatient hospital growth
Revenue
$39.08M
Diluted EPS
$0.30
Gross margin
95.9%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q4
2025-03-25
CorMedix Inc. Q4 FY2024 Earnings Call
Confident tone Commercial launch and revenue ramp Large dialysis organization (LDO) customer Inpatient commercialization strategy
Results not yet reported
Audio Transcript Slides 8-K10-K
Earnings call
FY24 · Q3
2024-10-30
CorMedix Inc. Q3 FY2024 Earnings Call
Confident tone DefenCath Commercial Launch Dialysis Customer Expansion Adult TPN Clinical Program
Revenue
$11.46M
Diluted EPS
$-0.05
Gross margin
94.0%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q2
2024-08-14
CorMedix Inc. Q2 FY2024 Earnings Call
Confident tone DefenCath commercial launch (inpatient and outpatient) TDAPA and Medicare Advantage reimbursement TPN label expansion opportunity
Revenue
$806,119
Diluted EPS
$-0.25
Gross margin
36.8%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q1
2024-05-09
CorMedix Inc. Q1 FY2024 Earnings Call
Confident tone Commercial launch of DefenCath Label expansion and pediatric study Post-marketing real-world evidence studies
Diluted EPS
$-0.25
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q4
2024-03-12
CorMedix Inc. Q4 FY2023 Earnings Call
Confident tone DefenCath commercial launch Reimbursement and CMS review Hospital formulary adoption process
Results not yet reported
Audio Transcript Slides 8-K10-K
Earnings call
FY23 · Q3
2023-11-14
CorMedix Inc. Q3 FY2023 Earnings Call
Diluted EPS
$-0.17
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q2
2023-08-08
CorMedix Inc. Q2 FY2023 Earnings Call
Diluted EPS
$-0.25
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q1
2023-05-15
CorMedix Inc. Q1 FY2023 Earnings Call
Diluted EPS
$-0.24
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q4
2023-03-30
CorMedix Inc. Q4 FY2022 Earnings Call
Revenue
$29,702*
▼ 47.3% YoY
Gross margin
98.6%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY22 · Q3
2022-11-10
CorMedix Inc. Q3 FY2022 Earnings Call
Revenue
$6,817
▼ 82.1% YoY
Diluted EPS
$-0.17
Gross margin
78.5%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q2
2022-08-11
CorMedix Inc. Q2 FY2022 Earnings Call
Revenue
$21,253
▲ 159.5% YoY
Diluted EPS
$-0.19
Gross margin
98.4%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q1
2022-05-12
CorMedix Inc. Q1 FY2022 Earnings Call
Revenue
$7,636
▼ 91.3% YoY
Diluted EPS
$-0.18
Gross margin
80.0%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q4
2022-03-29
CorMedix Inc. Q4 FY2021 Earnings Call
Revenue
$56,396*
▲ 1.2% YoY
Gross margin
14.9%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY21 · Q3
2021-11-09
CorMedix Inc. Q3 FY2021 Earnings Call
Revenue
$38,088
▼ 59.1% YoY
Diluted EPS
$-0.22
Gross margin
33.9%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q2
2021-08-12
CorMedix Inc. Q2 FY2021 Earnings Call
Revenue
$8,191
▼ 50.2% YoY
Diluted EPS
$-0.12
Gross margin
-76.1%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q1
2021-05-14
CorMedix Inc. Q1 FY2021 Earnings Call
Revenue
$88,261
▲ 19.2% YoY
Gross margin
30.5%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY20 · Q4
2021-03-30
CorMedix Inc. Q4 FY2020 Earnings Call
Revenue
$55,714*
▲ 124.9% YoY
Gross margin
-2.7%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY20 · Q3
2020-11-05
CorMedix Inc. Q3 FY2020 Earnings Call
Revenue
$93,020
▲ 56.3% YoY
Gross margin
14.1%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY20 · Q2
2020-08-10
CorMedix Inc. Q2 FY2020 Earnings Call
Revenue
$16,443
▼ 53.4% YoY
Gross margin
-16.7%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY20 · Q1
2020-05-11
CorMedix Inc. Q1 FY2020 Earnings Call
Revenue
$74,054
▼ 54.8% YoY
Gross margin
34.5%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY19 · Q4
2020-03-16
CorMedix Inc. Q4 FY2019 Earnings Call
Revenue
$24,778*
▼ 6.6% YoY
Gross margin
-86.2%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Showing 1–27 of 27 earnings calls
Key facts CIK 1410098 CUSIP 21900C308 13F (30d) 187 filings 185 filers Visit website Investor relations

Report a Problem

Category
Description
Email (optional, for follow-up)